Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Published In:
- Lancet (London, England), 394(10193), 121-130 (2019)
- Authors:
- Gerstein, Hertzel C(4), Colhoun, Helen M(4), Dagenais, Gilles R, Diaz, Rafael, Lakshmanan, Mark, Pais, Prem, Probstfield, Jeffrey, Riesmeyer, Jeffrey S, Riddle, Matthew C, Rydén, Lars, Xavier, Denis, Atisso, Charles Messan, Dyal, Leanne, Hall, Stephanie, Rao-Melacini, Purnima, Wong, Gloria, Avezum, Alvaro, Basile, Jan, Chung, Namsik, Conget, Ignacio, Cushman, William C, Franek, Edward, Hancu, Nicolae, Hanefeld, Markolf, Holt, Shaun, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A, Lopez-Jaramillo, Patricio, Cardona Munoz, Ernesto German, Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J, Shaw, Jonathan E, Sheu, Wayne H-H, Temelkova-Kurktschiev, Theodora
- Database ID:
- RPEP-04190
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04190APA
Gerstein, Hertzel C; Colhoun, Helen M; Dagenais, Gilles R; Diaz, Rafael; Lakshmanan, Mark; Pais, Prem; Probstfield, Jeffrey; Riesmeyer, Jeffrey S; Riddle, Matthew C; Rydén, Lars; Xavier, Denis; Atisso, Charles Messan; Dyal, Leanne; Hall, Stephanie; Rao-Melacini, Purnima; Wong, Gloria; Avezum, Alvaro; Basile, Jan; Chung, Namsik; Conget, Ignacio; Cushman, William C; Franek, Edward; Hancu, Nicolae; Hanefeld, Markolf; Holt, Shaun; Jansky, Petr; Keltai, Matyas; Lanas, Fernando; Leiter, Lawrence A; Lopez-Jaramillo, Patricio; Cardona Munoz, Ernesto German; Pirags, Valdis; Pogosova, Nana; Raubenheimer, Peter J; Shaw, Jonathan E; Sheu, Wayne H-H; Temelkova-Kurktschiev, Theodora. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.. Lancet (London, England), 394(10193), 121-130. https://doi.org/10.1016/S0140-6736(19)31149-3
MLA
Gerstein, Hertzel C, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.." Lancet (London, 2019. https://doi.org/10.1016/S0140-6736(19)31149-3
RethinkPeptides
RethinkPeptides Research Database. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (..." RPEP-04190. Retrieved from https://rethinkpeptides.com/research/gerstein-2019-dulaglutide-and-cardiovascular-outcomes
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.